Skip to main content
VulnerabilityPublished

CVE-2026-18068: IBM · Information Exposure

Affects IBMSource CVE Database V5

0

Not known to be exploited · CVSS 4.3 Medium.

Data as of 26 Oct 2026, 17:16 UTC

CVSS 3.1 base score
4.3Medium
How severe the flaw is on the 0–10 CVSS scale.
EPSS
0.3% chance of exploitation in 30 days – higher than 30% of CVEsExploit Prediction Scoring System: the likelihood attackers will use this flaw soon.
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N

Exploitation evidence

  1. Disclosed: evidence found.

    CVE published 13 Aug 2026

  2. Detectable: no evidence on record.

    No public nuclei template indexed

  3. Weaponised: no evidence on record.

    No public exploit code indexed in Metasploit or Exploit-DB

  4. Exploited in the wild: no evidence on record.

    Not in CISA KEV and no source reports exploitation

  5. Observed by OffSeq Mirage: no evidence on record.

    No attack traffic recorded by OffSeq Mirage sensors

A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 26 Oct 2026.

What to do

Affected software

ProductAffectedFixed in
IBMAffected
  • 7.3 – 7.6
4 affected builds
Fixed in–

CPE configurations (8)

  • cpe:2.3:a:ibm:i:7.6:*:*:*:*:*:*:*
  • cpe:2.3:a:ibm:i:7.6.0:*:*:*:*:*:*:*
  • cpe:2.3:a:ibm:i:7.5:*:*:*:*:*:*:*
  • cpe:2.3:a:ibm:i:7.5.0:*:*:*:*:*:*:*
  • cpe:2.3:a:ibm:i:7.4:*:*:*:*:*:*:*
  • cpe:2.3:a:ibm:i:7.4.0:*:*:*:*:*:*:*

AI-suggested

Until an official fix is released, monitor IBM security advisories for updates. No specific mitigation or workaround is currently documented.

Description

CVE-2026-18068 is a medium severity vulnerability in IBM i versions 7.3, 7.4, 7.5, and 7.6. It involves a confusion between byte-count and element-count that could allow a remote attacker with limited privileges to obtain sensitive information. The vulnerability does not impact integrity or availability and does not require user interaction. No official patch or remediation guidance is currently confirmed.

References

Community reviews

Loading reviews…